Ernexa Therapeutics Inc. 8-K

What Happened
Ernexa Therapeutics Inc. (ERNA) filed an 8‑K reporting that Senior Vice President of Finance Sandra Gurrola delivered her resignation on June 22, 2026, with the resignation effective July 3, 2026. The company said her departure is not due to any disagreement with the company’s operations, policies, or practices. Ms. Gurrola has agreed to provide transition assistance on a part‑time basis (up to 10 hours per week) through the filing of the Company’s Form 10‑Q for the quarter ended June 30, 2026.

Key Details

• Filing: Form 8‑K filed June 26, 2026 (resignation given June 22, 2026; effective July 3, 2026).
• Transition support: up to 10 hours per week through the June 30, 2026 Form 10‑Q filing.
• Compensation: Company has not yet determined any pay for transition services; will disclose any material arrangements as required by SEC rules.
• Succession: Company has begun a search for a successor and expects to use outside support for finance, accounting, and reporting until a replacement is appointed.

Why It Matters
A senior finance leader’s departure can affect continuity in financial reporting and oversight. Investors should note the short-term transition plan (part‑time support and external assistance) and watch for future disclosures about a permanent finance officer appointment or any material compensation arrangements tied to the resignation. The company’s statement that there was no disagreement reduces immediate governance concerns, but ongoing updates (new hire, interim arrangements) are relevant for evaluating financial controls and reporting reliability.